StreetSmart Live! Presents Frank Holmes’ Virtual Junior Mining Expo on 11/12/2020. Learn More

Sector Expert: Dr. KSS

BioPub.co

Dr. KSS is the founder and editor-in-chief of BioPub.co. He is an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, he has been investing in biotech companies with great success. Dr. KSS earned his degrees at a top 10 U.S. institution, where he was an NIH scholar and graduated with top honors. He has extensive post-doctoral research experience and am board certified in internal medicine and also gastroenterology. His goal is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities.

Subscribe to
Streetwise Reports

Companies Commented On

  • Acurx Pharmaceuticals LLC


Recent Interviews

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury (10/19/20)
Brain graph

Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co.

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space? (8/10/20)
Gastrointestinal

Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile.

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals (8/3/20)
pillsperiodictable

Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years.



Due to permission requirements, not all quotes are shown.